Literature DB >> 35599231

Cancer cell cycle dystopia: heterogeneity, plasticity, and therapy.

Agnieszka K Witkiewicz1, Vishnu Kumarasamy2, Ioannis Sanidas2, Erik S Knudsen3.   

Abstract

The mammalian cell cycle has been extensively studied regarding cancer etiology, progression, and therapeutic intervention. The canonical cell cycle framework is supported by a plethora of data pointing to a relatively simple linear pathway in which mitogenic signals are integrated in a stepwise fashion to allow progression through G1/S with coordinate actions of cyclin-dependent kinases (CDK)4/6 and CDK2 on the RB tumor suppressor. Recent work on adaptive mechanisms and intrinsic heterogeneous dependencies indicates that G1/S control of the cell cycle is a variable signaling pathway rather than an invariant engine that drives cell division. These alterations can limit the effectiveness of pharmaceutical agents but provide new avenues for therapeutic interventions. These findings support a dystopian view of the cell cycle in cancer where the canonical utopian cell cycle is often not observed. However, recognizing the extent of cell cycle heterogeneity likely creates new opportunities for precision therapeutic approaches specifically targeting these states.
Copyright © 2022 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CDK4; CDK6; CHK1; RB; abemaciclib; ambra1; aurora kinase; cyclin D1; cyclin E; p16(INK4A); p27(KIP1); palbociclib

Mesh:

Substances:

Year:  2022        PMID: 35599231      PMCID: PMC9388619          DOI: 10.1016/j.trecan.2022.04.006

Source DB:  PubMed          Journal:  Trends Cancer        ISSN: 2405-8025


  144 in total

1.  Role for E2F in control of both DNA replication and mitotic functions as revealed from DNA microarray analysis.

Authors:  S Ishida; E Huang; H Zuzan; R Spang; G Leone; M West; J R Nevins
Journal:  Mol Cell Biol       Date:  2001-07       Impact factor: 4.272

Review 2.  CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought.

Authors:  Mary E Klein; Marta Kovatcheva; Lara E Davis; William D Tap; Andrew Koff
Journal:  Cancer Cell       Date:  2018-05-03       Impact factor: 31.743

3.  Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes.

Authors:  A S Lundberg; R A Weinberg
Journal:  Mol Cell Biol       Date:  1998-02       Impact factor: 4.272

Review 4.  Integrating Old and New Paradigms of G1/S Control.

Authors:  Seth M Rubin; Julien Sage; Jan M Skotheim
Journal:  Mol Cell       Date:  2020-09-17       Impact factor: 17.970

5.  Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial.

Authors:  Stephen Johnston; Shannon Puhalla; Duncan Wheatley; Alistair Ring; Peter Barry; Chris Holcombe; Jean Francois Boileau; Louise Provencher; André Robidoux; Mothaffar Rimawi; Stuart A McIntosh; Ibrahim Shalaby; Robert C Stein; Michael Thirlwell; David Dolling; James Morden; Claire Snowdon; Sophie Perry; Chester Cornman; Leona M Batten; Lisa K Jeffs; Andrew Dodson; Vera Martins; Arjun Modi; C Kent Osborne; Katherine L Pogue-Geile; Maggie Chon U Cheang; Norman Wolmark; Thomas B Julian; Kate Fisher; Mairead MacKenzie; Maggie Wilcox; Cynthia Huang Bartlett; Maria Koehler; Mitch Dowsett; Judith M Bliss; Samuel A Jacobs
Journal:  J Clin Oncol       Date:  2018-12-06       Impact factor: 44.544

6.  Cloning of a human cDNA encoding a CDC2-related kinase by complementation of a budding yeast cdc28 mutation.

Authors:  J Ninomiya-Tsuji; S Nomoto; H Yasuda; S I Reed; K Matsumoto
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-15       Impact factor: 11.205

7.  INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase Inhibitors.

Authors:  Qing Li; Baishan Jiang; Jiaye Guo; Hong Shao; Isabella S Del Priore; Qing Chang; Rei Kudo; Zhiqiang Li; Pedram Razavi; Bo Liu; Andrew S Boghossian; Matthew G Rees; Melissa M Ronan; Jennifer A Roth; Katherine A Donovan; Marta Palafox; Jorge S Reis-Filho; Elisa de Stanchina; Eric S Fischer; Neal Rosen; Violeta Serra; Andrew Koff; John D Chodera; Nathanael S Gray; Sarat Chandarlapaty
Journal:  Cancer Discov       Date:  2021-09-20       Impact factor: 38.272

8.  Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors.

Authors:  Shom Goel; Qi Wang; April C Watt; Sara M Tolaney; Deborah A Dillon; Wei Li; Susanne Ramm; Adam C Palmer; Haluk Yuzugullu; Vinay Varadan; David Tuck; Lyndsay N Harris; Kwok-Kin Wong; X Shirley Liu; Piotr Sicinski; Eric P Winer; Ian E Krop; Jean J Zhao
Journal:  Cancer Cell       Date:  2016-03-14       Impact factor: 31.743

9.  Cyclin E2, a novel G1 cyclin that binds Cdk2 and is aberrantly expressed in human cancers.

Authors:  J M Gudas; M Payton; S Thukral; E Chen; M Bass; M O Robinson; S Coats
Journal:  Mol Cell Biol       Date:  1999-01       Impact factor: 4.272

10.  A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.

Authors:  M Serrano; G J Hannon; D Beach
Journal:  Nature       Date:  1993-12-16       Impact factor: 49.962

View more
  1 in total

Review 1.  AMBRA1 and its role as a target for anticancer therapy.

Authors:  Xiang Li; Yuan Lyu; Junqi Li; Xinjun Wang
Journal:  Front Oncol       Date:  2022-09-27       Impact factor: 5.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.